Clinical trials: Controlled Human Infection
Influenza
Phase 1/2 Study of a Plant-Based Seasonal Recombinant Trivalent VLP Influenza Vaccine
This Phase 1/2 study is intended to assess the safety, tolerability, and immunogenicity of recombinant TVLP in adults 18-64 and 65 years of age and above and to confirm the dose(s) to be developed further in these two age cohorts.
- Trial name
- NCT07291635
- Testing
- Recombinant Influenza vaccine candidate, Commercial Influenza vaccine
- Where
- 7 sites in Canada
- Volunteers
- 728 people, healthy volunteers welcome
- Sponsor
- Aramis Biotechnologies Inc.
Upper Respiratory Disease, Influenza
Immune Defense Protein Impact On Respiratory Immune Outcomes
The primary goal of this study is to observe the impact of the IDP® Supplement on the duration and severity of upper respiratory symptoms in older individuals during the cold and flu season.
- Conditions
- Upper Respiratory Disease, Influenza, Viral Upper Respiratory Infection
- Trial name
- NCT07431840
- Testing
- Immune Defense Protein 50mg Dose, IDP 200mg Dose
- Where
- United States
- Volunteers
- 300 people, healthy volunteers welcome
- Sponsor
- Quantec Ltd
Malaria (Plasmodium Falciparum)
Controlled Human Malaria Infection by Mosquito Bites Using a Local Strain of Plasmodium Falciparum
The project aims to reproduce the malaria infection cycle using African mosquitoes, namely Anopheles gambiae and a local strain of Plasmodium parasites.
- Trial name
- BB-LaCHMI-01 (NCT07816497)
- Testing
- Controlled Human Malaria Infection
- Where
- Gabon
- Volunteers
- 20 people, healthy volunteers welcome
- Sponsor
- Centre de Recherche Médicale de Lambaréné
Exposure to Hepatitis B Virus
Safety and Efficacy Study of Adjuvanted Prophylactic Hepatitis B Vaccine
There is a need for more effective and better-tolerated hepatitis B vaccines for low responder high-risk populations including patients with renal impairment and/or diabetes mellitus and those aged over 40 years.
- Trial name
- NCT01951677
- Testing
- HBsAg, PreS HBsAg, Advax-1(TM)
- Where
- Australia
- Volunteers
- 240 people, healthy volunteers welcome
- Sponsor
- Vaxine Pty Ltd
Human Papillomavirus (HPV) Infection, HPV Vaccination Acceptance/Intention
Effect of Different HPV Education Methods on Vaccination Intention in Young Women
Detailed Description Human papillomavirus (HPV) is one of the leading causes of cervical cancer and can be prevented by vaccination.
- Trial name
- NCT07420556
- Testing
- Video-Based HPV Education, Face-to-Face HPV Education
- Where
- Turkey (Türkiye)
- Volunteers
- 159 people, healthy volunteers welcome
- Sponsor
- Emel GÜÇLÜ CİHAN
Hepatitis B
Consistency of 3 Consecutive Lots of a Novel HBV Vaccine With Single-blind Safety Evaluation Using Engerix™-B as Control
The purpose of the present study is to evaluate the immunogenicity and safety of three consecutive production lots of the novel adjuvanted HBV vaccine.
- Trial name
- NCT00697866
- Testing
- HBV-MPL vaccine 208129, Engerix™-B
- Volunteers
- 951 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Influenza
Safety and Efficacy Study of Fluzone® Vaccine Combined With Different Doses of JVRS-100 Adjuvant
This study is designed to assess safety, tolerability and immunogenicity of Fluzone® vaccine with four dose levels of JVRS-100 adjuvant compared to Fluzone® vaccine alone in healthy adults 18-49 years of age.
- Trial name
- H-100-001 (NCT00662272)
- Testing
- Fluzone vaccine with JVRS-100 adjuvant, Fluzone vaccine
- Where
- 2 sites in United States
- Volunteers
- 128 people, healthy volunteers welcome
- Sponsor
- Colby Pharmaceutical Company
Chronic Hepatitis B
A Study of ALG-000184 Drug to Evaluate Safety, Tolerability, Pharmacokinetics and Pharmacodynamics After Single and Multiple Doses in Healthy Volunteers and CHB Subjects
The goal of this clinical trial is to learn if ALG-000184 is safe, well-tolerated, and works to treat chronic hepatitis B virus (HBV) infection.
- Trial name
- NCT04536337
- Testing
- ALG-000184, Entecavir
- Where
- 10 sites in Australia, China and 4 more
- Volunteers
- 165 people, healthy volunteers welcome
- Sponsor
- Aligos Therapeutics
Human Immunodeficiency Virus
Acceptability, Feasibility and Impact of Oral HIV Self-testing for Partner Testing Among Kenyan Adolescent Girls Aged 15-19 Years: A Randomized Controlled Trial
This randomized controlled trial will assess the feasibility, acceptability and impact of the provision of multiple oral-fluid based HIV self-test kits to HIV-negative adolescents aged 15-19 years to promote HIV testing among…
- Trial name
- NCT04805112
- Testing
- Provision of multiple self-tests
- Where
- Kenya
- Volunteers
- 349 people, healthy volunteers welcome
- Sponsor
- University of Pennsylvania
Malaria
Controlled Human Malaria Infection by Intradermal Injection of Plasmodium Falciparum Sporozoites in Tanzanian Adults
The proposed trial will evaluate whether relatively non immune populations in endemic countries can be effectively infected with aseptic, purified, cryopreserved sporozoites (PfSPZ Challenge) given intradermally.
- Trial name
- NCT01540903
- Testing
- PfSPZ Challenge, Saline
- Where
- Tanzania
- Volunteers
- 30 people, healthy volunteers welcome
- Sponsor
- Sanaria Inc.
Chronic Hepatitis B Virus
A Multicenter, Randomized, Double-Blind, Placebo-Controlled Phase II Clinical Trial to Evaluate the Efficacy and Safety of TVAX-008 Injection in Treated Patients With Chronic Hepatitis B
The objective of this study was to evaluate the efficacy and safety of TVAX-008 Injection in a multicenter, randomized, double-blind, placebo-controlled, parallel-group Phase II clinical trial in NAs-treated subjects with chronic…
- Trial name
- NCT07190742
- Testing
- TVAX-008
- Where
- China
- Volunteers
- 80 people, healthy volunteers welcome
- Sponsor
- Grand Theravac Life Sciences (Nanjing) Co., Ltd.
HPV Infection, HPV-Related Cervical Carcinoma
A Randomized, Blinded, Placebo-controlled Phase I Clinical Trial Evaluating the Safety and Preliminary Immunogenicity of a 11-valent Recombinant Human Papillomavirus Vaccine (Hansenulapolymorpha) in Chinese Women Aged 9-45 Years
A total of 90 Chinese women aged 9-45 years old were divided into three age groups: 27-45 years old, 18-26 years old, and 9-17 years old. The experimental group and the placebo group were randomly assigned in a ratio of 2:1.
- Trial name
- NCT04083196
- Testing
- 11-valent recombinant human papilloma virus vaccine (Hansenula polymorpha)
- Where
- China
- Volunteers
- 90 people, healthy volunteers welcome
- Sponsor
- National Vaccine and Serum Institute, China
Whooping Cough
A Phase I Clinical Study of a GamLPV, a Live Intranasal Bordetella Pertussis Vaccine
The study contains three periods: screening, inpatient hospitalization and follow-up. And should be leaded as a randomized placebo-controlled study with in chain order enrolled volunteers and dose escalating.
- Trial name
- NCT03137927
- Testing
- Vaccine GamLPV
- Where
- Russia
- Volunteers
- 36 people, healthy volunteers welcome
- Sponsor
- Gamaleya Research Institute of Epidemiology and Microbiology, Health Ministry of the Russian Federation
Infection, Human Immunodeficiency Virus
Single and Repeated Dose Escalation Study of GSK2838232
GSK2838232 is a Human Immunodeficiency Virus (HIV) maturation inhibitor being developed for the treatment of HIV in combination with other antiretroviral therapy (ART).
- Trial name
- NCT02795754
- Testing
- GSK2838232 PIB, GSK2838232 IR1, GSK2838232 IR2
- Where
- United States
- Volunteers
- 62 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Hepatitis B Vaccines
Robust Antibody and Cytokine Response to Hepatitis B Vaccine Among Not-in-treatment Patients With Chronic Hepatitis C：An Open-label Control Study in China
Background Hepatitis B virus (HBV) co-infection in individuals with hepatitis C virus (HCV) can enhance the severity of hepatitis and the risks of liver cirrhosis and hepatocellular carcinoma (HCC).
- Trial name
- NCT02898922
- Testing
- hepatitis B vaccine made by Recombinant DNA Techniques in Saccharomyces Cerevisiae
- Volunteers
- 300 people, healthy volunteers welcome
- Sponsor
- Shandong Province Centers for Disease Control and Prevention
Prophylaxis of Avian Influenza
Immunogenicity, Safety and Tolerability of Two Doses of a Pre-pandemic Influenza Vaccine in Participants Aged 6 Months to 17 Years
Evaluate the immune response and reactogenicity of H5N1 vaccination in subjects aged 6 months to 17 years compared to seasonal flu vaccination
- Trial name
- NCT00537524
- Testing
- H5N1 Influenza Vaccine
- Where
- Finland
- Volunteers
- 471 people, healthy volunteers welcome
- Sponsor
- Novartis Vaccines
HPV InfectioN, HPV-Related Carcinoma
A Study to Evaluate the Efficacy, Safety, and Immunogenicity of SCT1000 in Healthy Women Aged 18-45 Years
A total of 18000 healthy women aged 18-45 years old were divided into three age groups: 18-26 years old, 27-35 years old, and 36-45 years old. The experimental group and the placebo group were randomly assigned in a ratio of 1:1.
- Trial name
- NCT06041061
- Testing
- Recombinant 14-Valent Human Papillomavirus Vaccine（Insect Cell）
- Where
- 5 sites in China
- Volunteers
- 18,000 people, healthy volunteers welcome
- Sponsor
- Sinocelltech Ltd.
Healthy Volunteers
A Double-blind Randomized Placebo-controlled Study Study of the Safety, Reactogenicity and Immunogenicity of the GamFluVac
The aim of the present study is at the first stage: a comparative assessment of the safety of the two methods of vaccine administration, at the second - an assessment of the safety and state of post-vaccination immunity at…
- Trial name
- NCT04034290
- Testing
- GamFluVac
- Where
- Russia
- Volunteers
- 224 people, healthy volunteers welcome
- Sponsor
- Gamaleya Research Institute of Epidemiology and Microbiology, Health Ministry of the Russian Federation
Leishmaniasis, Cutaneous, Insect Bites
A Clinical Study to Develop an Uninfected Sand Fly Biting Protocol
The disease leishmaniasis mainly occurs in hot and tropical countries, affects millions of people and causes around 20,000 deaths across the world every year.
- Trial name
- FLYBITE (NCT03999970)
- Testing
- Sand fly bite
- Where
- United Kingdom
- Volunteers
- 12 people, healthy volunteers welcome
- Sponsor
- University of York
Hepatitis E Virus Infection
Immunogenicity and Safety of Hecolin® in HIV Positive/Negative Adults and in Children
The primary goal of this clinical trial is to demonstrate non-inferiority of 30 µg of Hecolin® in healthy children, compared to healthy adults as measured by seroresponse rates (SR) of anti-HEV IgG titers, 4 weeks after 3 doses…
- Trial name
- NCT06306196
- Testing
- Hecolin® Recombinant Hepatitis E Vaccine, Isotonic Sodium Chloride injection
- Where
- 3 sites in South Africa
- Volunteers
- 1,040 people, healthy volunteers welcome
- Sponsor
- International Vaccine Institute